Mustang Bio, Inc.
MBIO
$1.09
-$0.08-6.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -110.23% | -34.30% | -49.89% | -38.52% | -9.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -100.29% | -87.50% | -57.59% | -67.95% | -54.43% |
| Operating Income | 100.29% | 87.50% | 57.59% | 67.95% | 54.43% |
| Income Before Tax | 88.95% | 85.98% | 49.50% | 68.90% | 56.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 88.95% | 85.98% | 49.50% | 68.90% | 56.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.95% | 85.98% | 49.50% | 68.90% | 56.12% |
| EBIT | 100.29% | 87.50% | 57.59% | 67.95% | 54.43% |
| EBITDA | 100.90% | 87.64% | 58.01% | 68.23% | 54.17% |
| EPS Basic | 97.81% | 96.89% | 82.25% | 77.64% | 65.32% |
| Normalized Basic EPS | 100.20% | 97.26% | 87.98% | 77.64% | 64.05% |
| EPS Diluted | 97.81% | 96.89% | 82.25% | 77.64% | 65.32% |
| Normalized Diluted EPS | 100.20% | 97.26% | 87.98% | 77.64% | 64.05% |
| Average Basic Shares Outstanding | 405.04% | 350.92% | 184.62% | 39.04% | 26.53% |
| Average Diluted Shares Outstanding | 405.04% | 350.92% | 184.62% | 39.04% | 26.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |